Research programme: pain therapeutics - PhytoPain Pharma

Drug Profile

Research programme: pain therapeutics - PhytoPain Pharma

Alternative Names: PPP-001; PPTGR

Latest Information Update: 06 Oct 2016

Price : $50

At a glance

  • Originator PhytoPain Pharma
  • Class Analgesics; Cannabinoids; Small molecules
  • Mechanism of Action Cannabinoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Neuropathic pain

Most Recent Events

  • 04 Oct 2016 PhytoPain Pharma plans to file an IND application with the US FDA for Pain
  • 26 Sep 2016 Early research in Neuropathic pain in Canada (Inhalation)
  • 26 Sep 2016 Phytopain Pharma submits a request for designation to the US FDA's Center for Drug Evaluation and Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top